AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03226210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspart insulin or lipro insulin
Description: After completing OGTTS, enrolled subjects (new diagnosed T2DM) were randomly assigned into two groups: NovoRapid group (group Asp, Novo Nordisk, Bagsvaerd, Denmark) and Prandilin group (group Lis, Gan \& Lee pharmaceuticals, Beijing, China) in CSII, combined with metformin (Bristol-Myers Squibb, USA) therapy. During insulin intensive therapy, every patient general use 1.5g metformin per day. If the patient is unable to tolerate the side effects of metformin, such as diarrhea, nausea, vomiting, allergies, etc., the daily dose of metformin is reduced to 1.0g. If the patients are still unable to tolerate the daily 1.0g of metformin, exit from this study.
Study NCT04059003 — intervention group
Intervention type: DRUG
Intervention: Taxanes or/and anthracycline-based therapy
Description: Taxanes or/and anthracycline-based therapy will be used in this group. That is, intravenous injection of 90 mg/m2 epirubicin (trade name: Pharmorubicin, Pfizer, Shanghai, China; drug approval number: H20100155) + 135 mg/m2 paclitaxel liposome (trade name: Taxotere, Sanofi (Hangzhou) Pharmaceutical Co., Ltd., Hangzhou, China; drug approval number: J20090104), every 3 weeks as a course of treatment. The efficacy will be evaluated every 2 courses. After the 6th course, mastectomy will be performed according to the patient's conditions.
Study NCT02686047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYAJOINT Plus
Description: The patients in the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
Study NCT02686047 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One
Description: The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
Study NCT03868072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELJANZ 5Mg Tablet
Description: XELJANZ 5Mg Tablet 1T single oral administration under fasting
Study NCT03868072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chong Kun Dang Tofacitinib Tablet
Description: Chong Kun Dang Tofacitinib Tablet 1T single oral administration under fasting
Study NCT03774485 — intervention group
Intervention type: DEVICE
Intervention: G-Tech Gutcheck Myoelectric recording device
Description: Three G-Tech patches are placed on the abdomen of the patient to record myoelectric activity.
Study NCT01411839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT-AD)
Description: CBT-AD is a therapy program intervention that uses one-on-one and face-to-face patient-therapist sessions.
Study NCT01886378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX007
Study NCT01688830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Study NCT01688830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655075
Study NCT01688830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00005597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 200 mg/m\^2/day, PO, on Days 1-5 of each 28 day cycle.
Study NCT03801915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: 1 mg/kg or 3 mg/kg for pre-operative dose, 1 mg/kg during post-operative period
Study NCT03801915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreatectomy or hepatectomy
Description: Pancreatectomy or hepatectomy
Study NCT00446992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 16-week open trial of olanzapine. The patients were started on a dose of 15 mg/d by mouth, which could be adjusted to as low as 10 mg/d or as high as 40 mg/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.
Study NCT04210869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed Nuts
Description: Study volunteers will receive daily 60 g of mixed nuts (15 g walnut, 15 g cashew, 15 g hazelnut, 15 g pistachio) for 16 weeks.
Study NCT03435757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OFD+IMP+CPS
Description: open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty
Study NCT03435757 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD+IMP
Description: open flap debridement (OFD) and intramarrow penetration (IMP)
Study NCT00685633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide
Description: Given orally
Study NCT00685633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enzastaurin hydrochloride
Description: Given orally
Study NCT04061395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: See study arm description.
Study NCT01211288 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Astra implants
Description: Root form OsseoSpeed TX Astra Tech Implant System
Study NCT01211288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astra implants
Description: Root form OsseoSpeed TX Astra Tech Implant System
Study NCT00731120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate-release tablets
Study NCT00731120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo-matching capsules
Study NCT04169230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Single dose administration of citalopram (20mg)
Study NCT04169230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Single dose administration lactose placebo tablet
Study NCT05566496 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: All participants receive brain MRI evaluation and clinical evaluation of tic severity.
Study NCT03802942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucerna
Description: 1 bottle in the morning with breakfast and 1 bottle in the evening with dinner
Study NCT00520169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal ketamine
Description: A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.
Study NCT00520169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.
Study NCT01513980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: self-monitoring for patients with severe COPD
Description: Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor pulse-oxymetry and heart rate with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms. CAT questionnaire is monthly administrated by phone to the patients
Study NCT01513980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nurse-monitoring for patients with severe COPD
Description: A nurse is in charge of data collection during home visits with a frequency set by the lung specialist depending to the patient clinical conditions. The nurse uses portable biomedical devices to measure pulse-oxymetry, heart rate, spirometry and if scheduled an arterial blood gas test. Data are transmitted to the clinician who checks them on his laptop in the hospital and completes the visit with the medical report.
Study NCT02791945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Management Counseling
Description: Brief alcohol counseling
Study NCT02791945 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical Management Counseling
Description: Brief alcohol counseling
Study NCT02791945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Experimental supplement
Study NCT02791945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT03933527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: making staining beverage rinse during in-office tooth bleaching
Description: the subjects in experimental group should make staining beverage(coffee or tea) rinse for 30 second, four times daily.
Study NCT00795613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESCALATED BEACOPP
Description: Esc.BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 200 mg/m2/ev/die1°- 3° Doxorubicine35 mg/m2/ev/die 1° Cyclophosphamide1250 mg/m2/ev/die 1° Vincristine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/b.m./die 1°- 7° Prednison40 mg/m2/b.m./die 1°-14° G-CSF300mcg/die s/c from day 8 until PMN>1000/ul Recycle every 21 days Esc.R-BEACOPP as above plus Rituximab 375 mg/m2/ev/ die 1° Recycle every 21 days Baseline BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 100 mg/m2/ev/die 1°-3° Doxorubicine25 mg/m2/ev/die 1° Cyclophosphamide650 mg/m2/ev/die 1° Vincrinstine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/os/die 1°-7° Prednison40 mg/m2/os/die 1°-14° Recycle every 21 days Baseline R-BEACOPP as above plus Rituximab375 mg/m2/ev/ die 1° Recycle every 21 days
Study NCT02086578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast MRI
Study NCT02086578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast-Q© questionnaire
Study NCT02086578 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multi-Beam IMRT
Description: The radiation dose (50-50.4 Gy/25-28 fractions in approximately 5-6 weeks), treatment-planning and delivery aspects are according to departmental guidelines for breast IMRT.
Study NCT03278249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins Ketogenic Diet
Description: Less than 20 grams of carbohydrates per day
Study NCT02017405 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Serum-derived bovine immunoglobulin protein isolate (SBI)
Description: Serum-derived bovine immunoglobulin protein isolate is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. Serum-derived bovine immunoglobulin protein isolate does not contain any milk products such as lactose, casein, or whey. Serum-derived bovine immunoglobulin protein isolate is gluten-free, dye-free, and soy-free. Serum-derived bovine immunoglobulin protein isolate is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
Study NCT02017405 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Matching Placebo
Study NCT03299166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: Troriluzole, 140 mg capsules once daily (QD) orally for the first 4 weeks and 200 mg (140 mg+ 60 mg capsules QD) for an additional 8 weeks
Study NCT03299166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsule once daily (QD)
Study NCT01811992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L
Description: Two adenoviral vectors will be used, each to deliver one of the therapeutic genes. Both vectors are human serotype 5, replication-defective, first generation adenoviral vectors deleted in E1a and E3 viral encoding regions. Each vector will constitutively express their respective therapeutic transgene (i.e. HSV1-TK or Flt3L) under the control of the human cytomegalovirus promoter (hCMV). Valacyclovir treatment will begin 1-3 days after vector administration at a dose of 2 grams given orally 3X per day for 14 days. A second course of valacyclovir will be given beginning Week 10.~Radiation and chemotherapy will be administered as per standard of care.
Study NCT00905164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Capsules, 25 mg
Description: Topiramate Capsules, 2 x 25 mg
Study NCT00905164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® Capsules, 25 mg
Description: Topamax® Capsules, 2 x 25 mg
Study NCT03422900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diabetes-Specific enteral formula
Description: Complete enteral formula normocaloric hyperproteic with fiber (80% SOLUBLE)
Study NCT03422900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard formula
Description: Complete enteral formula normocaloric hormoproteic without fiber
Study NCT03059134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 25mg
Description: We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.
Study NCT03059134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 25mg
Description: We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.
Study NCT03908801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized water dance intervention
Description: Group activity in a warm pool (32-34 °C) led by two SWAN leaders. During each session, nine songs are played and the participants, assisted by a support person, perform dance movements rhythmically to the mood of the music. The songs are chosen to stimulate different movement patterns and to emphasize different emotions.
Study NCT00726063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nanotite dental implant
Description: Nanotite root form titanium dental implant
Study NCT00726063 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osseotite dental implant
Description: Osseotite Root form titanium dental implant
Study NCT00436696 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03111823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo aerobic exercise sessions
Study NCT03111823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03111823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Starting dose of Methotrexate of 15 mg once a week plus folic acid 1mg. daily.
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarilumab
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03414502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study NCT03763084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: For patients in the acetaminophen group, oral acetaminophen supplemented dexmedetomidine sedation will be provided after surgery.
Study NCT03763084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: For patients in the control group, sufentanil supplemented dexmedetomidine sedation will be provided after surgery.
Study NCT02705742 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Mesenchymal Stem Cells
Description: 1.000.000 (one million) cells/kg, IV of dose in the Peripheral vein and 3.000.000 (three million) cells/kg of dose into the right hepatic artery)
Study NCT02928887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue light
Description: Exposure to high illuminance (1000 lux), blue spectrum (480 nm) light for a 24-hour photoperiod immediately before surgery and a 24-hour photoperiod immediately after surgery
Study NCT00303069 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710
Description: Single dose of V710 (at dosages of 5 μg, 30 μg, or 90 μg) intramuscularly
Study NCT00303069 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Single dose of saline placebo intramuscularly
Study NCT01816217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation with The McGrath Mac videolaryngoscope
Study NCT04073173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: INSURE
Description: Patients will be intubated by endotracheal tube, exogenous surfactant (Poractant alfa) will be administered and then they will be extubated.
Study NCT04073173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISA
Description: Surfactant (Poractant alfa) will be directly delivered into the lungs via a fine bore catheter inserted into the trachea and then patients will be extubated.
Study NCT04073173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesic, Opioid
Description: Remifentanil (0.5-2 micrograms/kg/dose)
Study NCT00795613 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CONVENTIONAL ABVD
Description: ABVD(cycle repeats every 28 days) Doxorubicine25 mg/m2 iv days 1,15 Bleomicine10,000 units/m2 iv days 1,15 Vinblastine6 mg/m2 iv days 1,15 Dacarbazine375mg/m2 iv days 1,15 This will be given at full dose and on schedule,regardless of blood count.
Study NCT05994404 — intervention group
Intervention type: PROCEDURE
Intervention: ACDF
Study NCT05994404 — intervention group
Intervention type: PROCEDURE
Intervention: Posterior Cervical Fusion
Study NCT01959503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Progel Vascular Sealant
Study NCT01959503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelfoam Plus
Study NCT03010449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-bronchial valve and blood
Description: Intra-bronchial valve implantation in combination with autologous blood instillation
Study NCT03554525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat-binder damm
Description: 3 sticks every day during 12 months
Study NCT03554525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 sticks every day during 12 months
Study NCT03484754 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin
Description: injection of botulinum toxina in two different facial sites
Study NCT03484754 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin
Description: injection of botulinum toxina in two different facial sites